| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | SMJE00B | |||
| Carrier Free | PMJE00B | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC208F | |||
| Carrier Free | IC208P | |||
| Carrier Free | MAB208-SP | |||
| Carrier Free | MAB208-500 | |||
| Carrier Free | IC208V-100UG | |||
| Carrier Free | IC208U-100UG | |||
| Carrier Free | IC208T-100UG | |||
| Carrier Free | IC208S-100UG | |||
| Carrier Free | IC208R-100UG | |||
| Carrier Free | IC208N-100UG | |||
| Carrier Free | IC208G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 350-NS-010/CF | |||
| Carrier Free | 350-NS-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 350-NS-050/CF | |||
![N/A CXCL8/IL-8 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL8_DY208_ELISA_2307.jpg "N/A CXCL8/IL-8 [Biotin]")
![N/A CXCL8/IL-8 [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL8_IL8_D8050_ELISA_557.jpg "N/A CXCL8/IL-8 [HRP]")
![N/A CXCL8/IL-8 [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL8_IL8_D8050_ELISA_558.jpg)
![N/A CXCL8/IL-8 [HRP]](http://images.novusbio.com/fullsize2/CXCL8_D8000C_ELISA_378.jpg)
![Toll-like receptor 4 (TLR4) silencing decreases endogenous levels of pro-inflammatory cytokines. a Effect of TLR2/4 silencing in breast cancer cells transfected with negative control (nc) siRNA, or siRNA directed against TLR2 mRNA (si#1 and si#2) or TLR4 mRNA (si#1 and si#2) was analyzed using quantitative real-time PCR; ***P <0.001 (analysis of variance (ANOVA)). b IL-6 (left) and IL-8 (right) ELISA on supernatants from MDA-MB-231 breast cancer cells transfected with nc siRNA, or siRNA directed against TLR2 mRNA (si#1 and si#2) or TLR4 mRNA (si#1 and si#2); n = 4. Error bars standard error of the mean (SEM); *P <0.05, **P <0.01, ***P <0.001 (ANOVA). c Boyden chamber migration assays. Migration of primary human myeloid cells towards supernatants from different cell lines indicated. Human primary peripheral blood mononuclear cells were isolated as previously described [48] and allowed to migrate through a Costar Transwell® Permeable Support 8.0-μm 24-well plate (Corning) to the supernatants of breast cancer supernatants cultured under serum-free conditions. Percentage of migrated CD11b+ cells was analyzed using a flow cytometer and CD11b-APC antibodies (BD Sciences); n = 4. Error bars SEM; *P <0.05, **P <0.01, ***P <0.001 (ANOVA). d Matrigel invasion assays. Invasion of lipopolysaccharide (LPS)-stimulated/un-stimulated MDA-MB-231 cells into matrigel invasion chambers (BD Sciences) as indicated: 25 × 103 MDA-MB-231 cells were stimulated or not with LPS and allowed to invade from 72 h. Amount of invaded cells was analyzed using crystal violet staining and manual counting in four separate experiments; n = 4. Error bars SEM; *P <0.05, **P <0.01, ***P <0.001 (Student’s t test) Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26392082), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/d8000c_human-il-8-cxcl8-quantikine-elisa-kit-22820241795613.jpg)
![N/A CXCL1/GRO alpha/KC/CINC-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_CXCL1_DY453_ELISA_2039.jpg "N/A CXCL1/GRO alpha/KC/CINC-1 [Biotin]")
![N/A CCL2/JE/MCP-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_CCL2_DCP00_ELISA_633.jpg "N/A CCL2/JE/MCP-1 [HRP]")
![N/A CCL2/JE/MCP-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_CCL2_DCP00_ELISA_634.jpg)
![N/A CCL2/JE/MCP-1 [HRP]](http://images.novusbio.com/fullsize2/CCL2_DCP00_ELISA_67.jpg)
![N/A CCL2/JE/MCP-1 [HRP]](http://images.novusbio.com/fullsize2/CCL2_MJE00_ELISA_2619.jpg "N/A CCL2/JE/MCP-1 [HRP]")
![N/A CCL2/JE/MCP-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_CCL2_MJE00_ELISA_989.jpg)
![N/A CCL2/JE/MCP-1 [HRP]](http://images.novusbio.com/fullsize2/CCL2_MJE00_ELISA_281.jpg)
![N/A CCL2/JE/MCP-1 [HRP]](http://images.novusbio.com/fullsize2/CCL2_MJE00_ELISA_2620.jpg)
![N/A CXCL1/GRO alpha/KC/CINC-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL1_MKC00_ELISA_990.jpg "N/A CXCL1/GRO alpha/KC/CINC-1 [HRP]")
![N/A CXCL1/GRO alpha/KC/CINC-1 [HRP]](http://images.novusbio.com/fullsize2/CXCL1_MKC00_ELISA_423.jpg)
![N/A CXCL2/GRO beta/MIP-2/CINC-3 [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL2_MM200_ELISA_998.jpg "N/A CXCL2/GRO beta/MIP-2/CINC-3 [HRP]")
![N/A CXCL2/GRO beta/MIP-2/CINC-3 [HRP]](http://images.novusbio.com/fullsize2/CXCL2_MM200_ELISA_290.jpg)
![CXCR4 and CXCL12 expression in DLBCL. (a) Expression analysis of CXCR4 and CXCL12 in non-neoplastic control germinal center B cells (GC-B) and diffuse large B cell lymphoma cells (DLBCL) consisting of DLBCL-NGCB and DLCBL-GCB, by RQ-PCR. GCB-DLBCL were further subdivided into primary (DLBCL-pGCB) and transformed DLBCL (DLBCL-pGCB) originating from follicular lymphoma. (b) Expression analysis of CXCR4 and CXCL12 in DLBCL samples with early (stage 1) and advanced stage (stage 2–4) (left graphs) and DLBCL samples with and without bone marrow infiltration (right graphs) by RQ-PCR. (c) Probability of 5-year-survival in DLBCL patients (our cohort left panel and the cohort of Lenz et al. right [20]) stratified by the third quartile of CXCR4 expression, respectively. (d) Representative immunohistochemical stains of CXCR4 (I–III) and CXCL12 (IV–VI) on DLBCL samples (magnification 20×). mRNA expression levels were calculated as a relative expression in comparison to the GC-B cells. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31554271), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab350_human-mouse-cxcl12-sdf-1-mab-clone-79018-41202410331984.jpg)
![N/A CCL2/JE/MCP-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_CCL2_DY479_ELISA_2324.jpg "N/A CCL2/JE/MCP-1 [Biotin]")